{"url_path":"/sec/otlc/8-k/2026-07-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/908259/0001493152-26-033171-index.html","accession_number":"0001493152-26-033171","cik":"0000908259","ticker":"OTLC","issuer_name":"Oncotelic Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/908259/0001493152-26-033171-index.html","primary_entity_key":"0000908259","primary_entity_name":"Oncotelic Therapeutics, Inc."},"word_count":85,"has_tables":true,"body_markdown":"**Item\n9.01**\n**Financial\nStatements and Exhibits.**\n\n \n\n(d)\nExhibits.\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n \n**Incorporation\nby reference**\n\n \n \n \n \n \n\n10.1\n \n[Form of Restricted Stock Unit Grant Agreement](ex10-1.htm)\n \nFiled\nherewith\n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document).\n \n \n\n \n\n-2-\n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \nOncotelic\nTherapeutics, Inc.\n\n \n \n \n\nDate:\nJuly 14, 2026\n \n*/s/\nVuong Trieu*\n\n \nBy:\nVuong\nTrieu\n\n \n \nChief\nExecutive Officer\n\n \n\n-3-"}